Vital legislation is being introduced to protect #cancer patients by banning ads that suggest medical treatment is unnecessary for cancer treatment & prevent the vulnerable from being exposed to misinformation. Thank you Kate O'Connell TD, Irish Cancer Society, Dr Robert O'Connor and all who've worked to progress this. ow.ly/DDfZ30mYYJs... See MoreSee Less
Prof. Kater explains obinutuzumab-venetoclax #clinicaltrial combination; explaining how #venetoclax restores T-cell function through its targeting of #CLL cells & why future combinations with venetoclax may be very promising | via VJHemOnc ow.ly/9EJP30mWWLi... See MoreSee Less
The dysfunction of T-cells is widely observed in chronic lymphocytic leukemia (CLL). Here, Arnon Kater, MD, PhD, of the University of Amsterdam, Amsterdam, Netherlands, describes the promising data from the HOVON 139 (GIVE) trial (2015-004985-27), which investigated T-cell profiles in patients recei...
New research finds that "Mycoplasmas.... [which are] tiny bacteria contain a protein called DnaK ...weakens the effect of certain drugs that aim to boost the activity of the natural anticancer protein p53" | via Medical News Today ow.ly/I87P30mWgnn... See MoreSee Less
Feelings of shock, fear & helplessness may lead to Cancer-Related Post-traumatic stress... Certain factors that may predispose people to this include cancers that recur as in blood cancers... & the amount of social support available | via @BloodCancer_HU ow.ly/UHlP30mV1h2... See MoreSee Less
Our good friend #CLL patient & advocate Deborah Simms interviews the expert Prof. Peter Hillmen at #ASH18 who shares insights into combination therapies; MURANO #clinicaltrial; Minimal Residual Disease (MRD) & stopping treatment | via Leukaemia Care ow.ly/xaBS30mUiENChronic Lymphocytic Leukaemia (CLL) patient advocate Deborah Sims interviews Professor Peter Hillmen from Leeds about the data he's presenting at the America... ... See MoreSee Less
Last night we attended the @CiSCR #AWAREforAll event in St. James's Hospital on #clinicaltrials awareness. Only 3% of patients globally partake in trials & the reasons were discussed. The excellent speakers included #CLL patient Patrick Kivlehan who shared his very positive trial story. ... See MoreSee Less
Our friend Brian Koffman is blogging about #ASH18 which kicks off today in San Diego. We and those like us who couldn't make it are following for news on advances to help our #CLL community ♡ ow.ly/f0Qs30mPcbs... See MoreSee Less
Deborah Sims, #CLL patient and passionate advocate for our community discusses her experience accessing treatment which involved her leaving her young family in Australia to join a #clinicaltrial in the UK. youtu.be/Y4O9sIuEcpIThe Leukaemia Foundation presents an informational video from someone who has experienced blood cancer firsthand: Deborah Sims was diagnosed with chronic lym... ... See MoreSee Less
We're delighted that Brian Koffman Dr. John Byrd, Chris Dwyer & Lisa Minkove R.I.P. will be recognised at #ASH18 in the new #CLL Heroes awards ceremony, being held to recognise individuals who've made a difference to the #CLL community ♡ | CURE Magazine ow.ly/8o3j30mL8ia... See MoreSee Less
Henry Smith MP: Raising awareness of this ‘hidden’ cancer Awareness of symptoms among GPs and the wider public is the first step to reducing the impact of blood cancer. shar.es/aatepJ via @PoliticsHome ... See MoreSee Less
From diagnosis to recovery, blood cancer is different to other types of cancer. Chair of the Blood Cancer APPG Henry Smith says it is vital that the wider medical profession understand these difference.